GlycoVaxyn AG
This article was originally published in Start Up
Executive Summary
Historically, the method for producing glycoconjugate vaccines has been lengthy and complex with low yields, requiring two separate fermentation runs and numerous purification steps, as well as a tedious chemical conjugation step. In contrast, GlycoVaxyn AG's vaccine conjugates are produced in recombinant E. coli using a single fermentation run that includes the conjugation process, and subsequent downstream purifications.
You may also be interested in...
Start-Up Previews (09/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Eyes Still Have It," features profiles of Alacrity Biosciences, Eyeon Therapeutics, Mobius Therapeutics and OcuCure Therapeutics. Plus these Start-Ups Across Health Care: CyberHeart, GlycoVaxyn, TheraCardia and Vicus Therapeutics.
Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.